Sentences with phrase «over its drug price»

It aggressively ratcheted up spending to spread its influence in Washington and to have a louder say in the debates over drug prices.

Cost - cutting by health insurers and concerns over drug pricing have made CVS's pharma - benefits unit seem like a liability to some investors; and in the head - to - head fight, Walgreens has grabbed some market share.

But her underlying point isn't totally invalid — the furor over drug price hikes like Mylan's is forcing legislators and private companies alike to finally confront the issue head - on, and highlighting just how difficult the disparate and largely opaque American medical financing system makes it to address these problems in a serious way.

Pfizer also came under fire over drug price increases including a record $ 107 million fine by U.K. regulators for hiking an epilepsy treatment's price by 2,600 %.

With recent uproar over drug price hikes by Valeant (vrx), Mylan (myl) and Martin Shkreli, healthcare experts have reached a consensus: The system as we know it is officially broken.

And it's already in the hot seat over its drug price hikes, so it can't raise prices much further without risking another scandal.

Separately, state prosecutors in New York and Massachusetts are investigating Valeant over its drug pricing and programs that provide financial assistance to help patients cover out - of - pocket expenses for their medications.

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

Bayer said in a statement that it doesn't control the cost for patients at the pharmacy, because copays are determined by insurers and pharmacy - benefit managers — an argument that pharmaceuticals companies have long made when facing criticism over drug prices.

Put simply, I believe it's frankly hard to justify holding most individual biotech stocks for especially long periods of time because of the rather limited lifespan of their products, and the political blowback over drug prices in the United States.

Fears over drug pricing have weighed on the company but PBMs have not been in the cross-hairs like the drug makers.

Not exact matches

The drug at the heart of four lawsuits in New Jersey is insulin — «a century - old medicine that for most of its history cost $ 15 or less,» write Barrett and Langreth, but «whose list price has risen more than 270 percent over the past decade.»

Miller, chief investment officer at LMM, said he thinks the embattled drugmaker is «a completely different company» than the one that was under severe fire for jacking up drug prices, and could see returns of 25 percent to 30 percent per year over the next five years.

Mark Merritt, CEO of the Pharmaceutical Care Management Association (PCMA), a trade group representing the 10 largest traditional PBMs, says that while «drug prices have gone up more than we'd like» over the years, his members have saved employers 25 %.

Valeant has been at the center of a political firestorm over prescription medication costs and pharmaceutical companies, which depend more on acquiring or licensing existing therapies (and then raising their prices) rather than fueling R&D into new drugs.

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

Marathon had free reign over its pricing thanks to the lack of available Duchenne drug competitors.

Over in the House of Representatives, Democrats have also been hot on the tail of pharmaceutical companies that have jacked up the prices of some of their drugs, though they've making less headway than their Senate bipartisan counterparts.

He added that the media focuses on examples of individual drug price hikes, it has overlooked the fact that expense of drugs as a proportion of healthcare spending has remained «remarkably constant» over the years.

Biogen is among companies that have been singled out for criticism in recent months; the Wall Street Journal called out the company for hiking the price of MS drug Avonex — 21 times, and at an annual average rate of 16 % — over the past decade.

Lately pharma execs have been taking yet another volley of criticism over drug - pricing practices from Hillary Clinton and Marco Rubio — and plenty of others — without offering much in the way of a defense.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

The debate over high drug prices has been a red hot topic here and inspired a lot of anger and legislative threats, especially in the midst of the 2016 election cycle.

Although the FDA can't dictate prices or reject therapies over pricing concerns (they can only focus on safety and efficacy), the agency can encourage more competition through moves like this (as well as speedier approval pathways) which could spur drug makers to produce products that ultimately lower costs for patients — a goal cited by FDA Commissioner Scott Gottlieb in announcing the list.

Takeda's negotiations to acquire Valeant Pharmaceuticals International's Salix stomach - drug business have stalled over price disagreements, Reuters reported in November, citing people familiar with the matter.

In attacking Berkshire, Ackman was striking back after Buffett's business partner Charlie Munger last year called Valeant «deeply immoral» for its practice of raising drug prices, sparking a sort of long - distance feud over whose favorite stock was better.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

And the defiant stance actually may have boosted the drug maker's image at a time when Americans are skeptical about the pharmaceutical industry over high drug prices.

Investors couldn't chalk up the selloff to the concerns over drug - price gouging that have depressed other pharmaceutical shares: Zoetis zts, after all, makes medications for dogs — whose health care costs have yet to inspire Senate investigations.

«The manufacturer of a drug has no influence or control over the prices charged by a secondary wholesaler to a hospital or pharmacy,» reads part of a statement on the PhRMA web site, the industry's trade association group.

Big pharma has been a persistent villain in the public's consciousness over the past year in the wake of exorbitant drug price hikes, including on ancient medications.

The drug, given over four injections, costs $ 120,000 in the U.S. Bristol defends Yervoy's price tag, saying it reflects the survival benefit and the steep cost of the drug's development.

Ricks also addressed President Donald Trump's decision to lambast pharmaceutical companies over the price of prescription drugs, in his State of the Union address Tuesday evening.

Herper homes in on a relatively new class of super-powerful (and super expensive) cholesterol - busting drugs called PCSK9 inhibitors (which were just shown to reduce death from any cause, and particularly heart - related conditions), and how patients with staggeringly high cholesterol who would benefit from the treatments had to wrangle with insurance companies that refused to cover them over their high prices.

In January, Mallinckrodt raised its price to $ 36,382 a vial, according to the data provider Truven, but that wasn't far off what it cost back in 2015 when Medicare Part D, a prescription drug program, spent over $ 500 million on the drug, making it one of the top 20 expenses for the program, government data shows.

PBMs have come into the spotlight in the debate over soaring drug prices, with manufacturers accusing them of contributing to inflating costs.

While the drug maker has responded to the massive backlash over its extravagant price increase on the device by boosting its patient assistance programs and introducing an authorized generic EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.

In order for the drug to be cost effective, drugmakers should slash the price of the drug by over two thirds — to $ 4,536, when patients would be spending about $ 100,000 to keep themselves healthy, the researchers wrote in the JAMA article.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since Marathon won an approval to treat a condition that afflicts fewer than 200,000 Americans per year and has a dearth of treatment options (rather than trying to become an also - ran in the saturated steroid therapy field), it has carte blanche over the drug's pricing.

Not everyone will benefit: now that Republicans have swept the US government for the first time since 1928, it means Obamacare is over - just a matter of time - and Affordable Care Act - vulnerable stocks such as Universal Health Services, AmSurg and Mednax will likely plunge; on the other hand pure pharma stocks like MCK and ABC will benefit as rhetoric on drug pricing will diminish significantly, leading to more stable earnings if / when changes in drug pricing become more stable.

The price of insulin — a lifesaving drug — has reached record highs as Eli Lilly, Novo Nordisk and Sanofi raised prices more than 240 percent over the past decade to often over $ 300 a vial today, with price rises frequently in lockstep, according to information technology firm Connecture.

Congress remains at an impasse over the future of the Affordable Care Act, while employers and consumers are struggling under the weight of rising medical costs, including the soaring price of prescription drugs.

U.S. Food and Drug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricDrug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricdrug pricing.

The NEJM letter also analyzed the use of two drugs that remained stable in price over that time period, as a control group — nitroglycerin and dobutamine.

By acquiring Humana, Walmart gains preferential access to seniors through Humana Medicare advantage, and leverage over pharmaceutical manufacturers to negotiate for lower drug prices.

Martin Shkreli, the Turing Pharmaceuticals LLC executive who drew criticism in August over a dramatic jump in a prescription drug price, made headlines Thursday for a different kind of price increase: a seven-fold surge in the shares of a microcap pharmaceutical company.

September 2015: Storm erupts over Turing's price increase — from $ 13.50 to $ 750 a pill — for anti-parasitic drug Daraprim.

Congress is deadlocked over the future of the Affordable Care Act, and employers and consumers are struggling to contain rising medical costs, particularly skyrocketing drug prices.

He told NBC News that the decision to lower the price was a reaction to outrage over the increase in the price of the drug from $ 13.50 to $ 750 per pill.